PL – co-financed projects implemented

Increasing drug safety by implementing Celon Pharma S.A. in its own production innovative oral forms of three medicinal products used in the pharmacotherapy of cardiovascular diseases

FGF1 analogue: a new therapeutic target for non-alcoholic fatty liver disease and related metabolic diseases

Develop clinical candidates based on mRNA technology in 3 therapeutic areas (oncological, metabolic – AATD deficiency and viral – SARS-CoV2), as well as to develop and expand the competence of Celon Pharma S.A. in the area of pharmaceutical production in the area of mRNA

  CELONKO – “Development of modern biomarkers and development of an innovative FGFR kinases inhibitor”